[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Tse DT: Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Trans Am Ophthalmol Soc; 2005;103:337-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.
  • PURPOSE: To determine the effect of intra-arterial cytoreductive chemotherapy (IACC) as an adjunct of a multimodality protocol for the treatment of lacrimal gland adenoid cystic carcinoma (ACC).
  • Nine consecutive patients with lacrimal gland ACC were treated with IACC, followed by orbital exenteration and chemoradiotherapy.
  • This case series was compared with a series of seven patients treated by conventional local therapies.
  • Information analyzed included site of disease, histologic characteristics, extent of disease, local-regional recurrence or distant metastases, and disease-free survival time.
  • Gene analysis was performed on microdissected tissue samples.
  • Mutational allelotyping targeting nine genomic loci using 15 polymorphic microsatellite markers situated in proximity to known tumor suppressor genes serve as markers for the presence of gene deletion.
  • The effect of IACC was assessed by the radiographic response and survival outcome in comparison to a historical cohort of patients managed by conventional local therapies.
  • A fractional mutation index was used to compare the acquired mutational load between different tumors having nonidentical patterns of microsatellite informativeness.
  • RESULTS: The carcinoma cause-specific death rates between the two treatment groups was significant (P = .029, log-rank test).
  • The cumulative 5-year carcinoma cause-specific death rate was 16.7% in the IACC-treated group compared with 57.1% in the conventional treatment group.
  • CONCLUSIONS: The preliminary data suggest that IACC as an integral component of a multimodal treatment strategy is potentially effective in improving local disease control and overall disease-free survival in lacrimal gland ACC.

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Ophthalmol. 1999 Apr;27(2):145-8 [10379714.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):208-10 [10439164.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):219-23 [10439167.001]
  • [Cites] Br J Surg. 1963 Sep;50:833-7 [14068633.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1989 Apr;115(4):503-11 [2466470.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):551-7 [10701733.001]
  • [Cites] J Neurooncol. 1999;44(3):267-73 [10720206.001]
  • [Cites] J Hepatol. 2000 Jul;33(1):152-6 [10905599.001]
  • [Cites] Semin Cancer Biol. 2000 Jun;10(3):185-200 [10936068.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):165-72 [11040937.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1925-32 [11064349.001]
  • [Cites] J Cancer Res Clin Oncol. 2001;127(3):187-92 [11260864.001]
  • [Cites] J Pathol. 2001 Sep;195(1):80-6 [11568894.001]
  • [Cites] J Mol Diagn. 2001 Nov;3(4):129-32 [11687595.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):3021-9 [11712805.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1079-85, viii [11728933.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2349-56 [11745290.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2681-9 [11980668.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2002 Sep;18(5):315-8 [12352816.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):47-51 [12359350.001]
  • [Cites] Arch Pathol Lab Med. 2003 Feb;127(2):213-7 [12562238.001]
  • [Cites] Hepatology. 2003 Apr;37(4):871-9 [12668980.001]
  • [Cites] Int J Mol Med. 2003 May;11(5):621-5 [12684700.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jul;127(7):861-4 [12823043.001]
  • [Cites] Liver Transpl. 2003 Jul;9(7):664-71 [12827550.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2955-9 [12926143.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jan;127(1):87-91 [14752417.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2004 Jan;20(1):22-6 [14752305.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):871-5 [14871814.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):671-8 [15151207.001]
  • [Cites] Gynecol Oncol. 2004 Jul;94(1):115-20 [15262128.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1346-58 [15181452.001]
  • [Cites] Cancer. 1970 Mar;25(3):571-9 [5416827.001]
  • [Cites] Am J Ophthalmol. 1971 Jan;71(1 Pt 2):178-92 [5542123.001]
  • [Cites] Am J Surg. 1973 Oct;126(4):464-8 [4542726.001]
  • [Cites] Am J Ophthalmol. 1975 Jan;79(1):53-5 [162900.001]
  • [Cites] Mod Probl Ophthalmol. 1975;14:306-23 [170512.001]
  • [Cites] Am J Ophthalmol. 1976 Dec;82(6):905-9 [187061.001]
  • [Cites] Br J Ophthalmol. 1979 Sep;63(9):600-6 [486378.001]
  • [Cites] Aust N Z J Surg. 1980 Dec;50(6):597-602 [6937179.001]
  • [Cites] Plast Reconstr Surg. 1981 Oct;68(4):577-85 [6269133.001]
  • [Cites] Arch Otolaryngol. 1981 Dec;107(12):739-41 [6274284.001]
  • [Cites] Int Ophthalmol Clin. 1982 Spring;22(1):99-120 [6277818.001]
  • [Cites] Cancer Res. 1982 May;42(5):2059-62 [7199971.001]
  • [Cites] Laryngoscope. 1982 Mar;92(3):235-9 [6279995.001]
  • [Cites] Arch Otolaryngol. 1982 Apr;108(4):221-4 [6280657.001]
  • [Cites] Hum Pathol. 1982 Mar;13(3):219-25 [6281163.001]
  • [Cites] Can J Ophthalmol. 1982 Feb;17(1):3-9 [6282425.001]
  • [Cites] Am J Ophthalmol. 1982 Dec;94(6):785-807 [6295169.001]
  • [Cites] Cancer. 1983 Feb 1;51(3):402-7 [6571796.001]
  • [Cites] J Clin Oncol. 1984 May;2(5):498-504 [6547166.001]
  • [Cites] Cancer. 1984 Sep 1;54(5):794-9 [6331626.001]
  • [Cites] Am J Surg. 1984 Oct;148(4):539-41 [6486324.001]
  • [Cites] Radiother Oncol. 1983 Nov;1(2):101-7 [6680215.001]
  • [Cites] Ophthalmology. 1985 Jan;92(1):128-34 [2983279.001]
  • [Cites] Cancer Drug Deliv. 1983;1(1):69-77 [6544119.001]
  • [Cites] AJNR Am J Neuroradiol. 1986 Mar-Apr;7(2):343-8 [3082167.001]
  • [Cites] Cancer. 1986 Dec 1;58(11):2386-8 [3021314.001]
  • [Cites] Br J Ophthalmol. 1986 Oct;70(10):727-31 [3022787.001]
  • [Cites] Cancer Chemother Pharmacol. 1987;19(2):155-8 [3568273.001]
  • [Cites] J Clin Oncol. 1987 Jun;5(6):951-5 [3585449.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Sep;95(2):165-70 [3035459.001]
  • [Cites] Trans Am Ophthalmol Soc. 1987;85:312-9 [2833831.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1646-54 [2530317.001]
  • [Cites] J Neurosurg. 1990 Feb;72(2):285-8 [2295924.001]
  • [Cites] Arch Neurol. 1992 Jan;49(1):83-6 [1728268.001]
  • [Cites] Am J Ophthalmol. 1992 Apr 15;113(4):435-8 [1558119.001]
  • [Cites] Br J Ophthalmol. 1992 Jul;76(7):401-7 [1320924.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1993;9(1):47-50 [8382940.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jul;119(7):747-52 [8391275.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(12):756-8 [8408188.001]
  • [Cites] Am J Ophthalmol. 1993 Oct 15;116(4):508-9 [8213988.001]
  • [Cites] Ann Ophthalmol. 1993 Nov;25(11):422-6 [8109884.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1994 Mar;10(1):45-8 [8193073.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9871-5 [7937908.001]
  • [Cites] Laryngorhinootologie. 1996 Jan;75(1):38-42 [8851118.001]
  • [Cites] Am J Ophthalmol. 1997 Mar;123(3):398-9 [9063252.001]
  • [Cites] Ophthalmology. 1997 Sep;104(9):1475-9 [9307644.001]
  • [Cites] Ophthalmology. 1997 Oct;104(10):1622-5 [9331201.001]
  • [Cites] Arch Ophthalmol. 1998 Mar;116(3):315-21 [9514484.001]
  • [Cites] Arch Ophthalmol. 1998 May;116(5):613-6 [9596497.001]
  • [Cites] Arch Ophthalmol. 1998 Dec;116(12):1673-6 [9869804.001]
  • (PMID = 17057810.001).
  • [ISSN] 1545-6110
  • [Journal-full-title] Transactions of the American Ophthalmological Society
  • [ISO-abbreviation] Trans Am Ophthalmol Soc
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / P30 EY014801; United States / NEI NIH HHS / EY / P30-EY014801
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC1447581
  •  go-up   go-down


2. Zinzani PL, Stefoni V, Musuraca G, Tani M, Alinari L, Gabriele A, Marchi E, Pileri S, Baccarani M: Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer; 2004 May 15;100(10):2190-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
  • BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphoma is a specific clinicopathologic entity with gastric and nongastrointestinal site involvement.
  • Presenting sites included periorbital soft tissue (n = 8), lung (n = 5), skin (n = 5), salivary glands (n = 5), lacrimal glands (n = 5), and thyroid (n = 3).
  • Four patients, all treated with CVP, experienced disease recurrence and then achieved a second CR after FM salvage treatment.
  • No tumor recurrence was observed in patients with thyroid, lacrimal gland, or pulmonary lymphoma.
  • CONCLUSIONS: The fludarabine-containing FM regimen provided a relatively effective frontline (or salvage) treatment option for patients with nongastrointestinal Stage IE MALT lymphoma and probably was superior to CVP in terms of efficacy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA (Cytosine-5-)-Methyltransferase / antagonists & inhibitors. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Gastrointestinal Neoplasms. Humans. Male. Middle Aged. Prednisone / administration & dosage. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15139063.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; COP protocol 2
  •  go-up   go-down


3. Lee JI, Kim YZ, Lee EH, Kim KH: Skull base invasion of adenoid cystic carcinoma of the lacrimal gland : a case report. J Korean Neurosurg Soc; 2008 Oct;44(4):273-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skull base invasion of adenoid cystic carcinoma of the lacrimal gland : a case report.
  • Although adenoid cystic carcinoma (ACC) of the lacrimal gland is a rarely encountered orbital tumor, it invades intracranially more frequently than carcinomas of other glands in the head and neck.
  • A 52-year-old man underwent orbital exenteration and resection of intracranially extended tumor via a fronto-orbito-zygomatic approach in combination with a transfacial approach.
  • Histopathologically, the tumor showed perineural, vascular, and lymphatic invasion.
  • Additionally, he received radiotherapy (60 Gy) and adjuvant systemic cisplatin and 5-fluorouracil chemotherapy due to residual tumor in the orbit and systemic metastases (lung, ribs, and spines).
  • He was free of progression and recurrence at 6 months after treatment.
  • The authors report a case of skull base invasion by an ACC of the lacrimal gland to remind neurosurgeons planning intervention that this disease shows a tendency to invade intracranially.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Oncol. 2005 Mar;41(3):328-35 [15743696.001]
  • [Cites] Brain Tumor Pathol. 2000;17(3):159-63 [11310924.001]
  • [Cites] Arch Ophthalmol. 1998 May;116(5):613-6 [9596497.001]
  • [Cites] Arch Ophthalmol. 1998 Mar;116(3):315-21 [9514484.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):867-9 [8922205.001]
  • [Cites] Neurosurgery. 1996 Jun;38(6):1105-12; discussion 1112-3 [8727139.001]
  • [Cites] Br J Ophthalmol. 1992 Jul;76(7):401-7 [1320924.001]
  • [Cites] Ear Nose Throat J. 1991 Apr;70(4):218-22 [1651839.001]
  • [Cites] Can J Ophthalmol. 1982 Feb;17(1):3-9 [6282425.001]
  • [Cites] Br J Ophthalmol. 1979 Sep;63(9):600-6 [486378.001]
  • [Cites] Am J Ophthalmol. 1975 Jan;79(1):53-5 [162900.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):510-4, 516-7 [12199167.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1079-85, viii [11728933.001]
  • [Cites] Br J Plast Surg. 2001 Jul;54(5):467 [11428792.001]
  • [Cites] Pathol Int. 1998 Dec;48(12):981-4 [9952343.001]
  • (PMID = 19096692.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588318
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma / Metastasis / Prognosis / Skull base
  •  go-up   go-down


Advertisement
4. Boitte JP, Traoré J, Boukhet F, Mondié JM, Traoré M, Delbosc B: [Adenoid cystic carcinoma of the lacrimal gland in a 14-year-old girl]. J Fr Ophtalmol; 2006 Oct;29(8):937-40
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the lacrimal gland in a 14-year-old girl].
  • [Transliterated title] Carcinome adénoïde kystique de la glande lacrymale chez une enfant âgée de 14 ans.
  • The initial examination highlighted the existence of an intraorbital tumor with a moderate effect on visual function.
  • The diagnosis was cylindroma, or adenoid cystic carcinoma.
  • Neither chemotherapy nor radiation were used.
  • Intraorbital tumors in children present diagnostic and therapeutic problems in countries with limited medical resources.
  • Cylindromas or adenoid cystic carcinomas of the lachrymal gland are the second most common cause of epithelial tumors in this gland, which are characterized by a high degree of malignancy, a very high rate of recurrence, and a low survival rate at 5 years.
  • In a tropical environment, diagnostic and therapeutic difficulties are compounded by limits to comprehensive care for the child.
  • [MeSH-major] Carcinoma, Adenoid Cystic. Eye Neoplasms. Lacrimal Apparatus

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075512.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Goldblum D, Ghadjar P, Curschmann J, Greiner R, Aebersold D: Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study. Radiat Oncol; 2008;3:22
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study.
  • BACKGROUND: To use amifostine concurrently with radiochemotherapy (CT-RT) or radiotherapy (RT) alone in order to prevent dry eye syndrome in patients with malignancies located in the fronto-orbital region.
  • METHODS: Five patients (2 males, 3 females) with diagnosed malignancies (Non-Hodgkin B-cell Lymphoma, neuroendocrine carcinoma) involving the lacrimal gland, in which either combined CT-RT or local RT were indicated, were prophylactically treated with amifostine (500 mg sc).
  • Single RT fraction dose, total dose and treatment duration were individually adjusted to the patient's need.
  • Subjective and objective dry eye assessment was performed for the post-treatment control of lacrimal gland function.
  • The median total duration of RT was 29 days (range, 23 - 39 days) and the median total RT dose was 40 Gy (range, 36 - 60 Gy).
  • Median lacrimal gland exposure was 35.9 Gy (range, 16.8 - 42.6 Gy).
  • Very good partial or complete tumor remission was achieved in all patients.
  • The treatment was well tolerated without major toxic reactions.
  • Post-treatment control did not reveal in any patient either subjective or objective signs of a dry eye syndrome.
  • CONCLUSION: The addition of amifostine to RT/CT-RT of patients with tumors localized in orbital region was found to be associated with absence of dry eye syndrome.
  • [MeSH-major] Amifostine / therapeutic use. Dry Eye Syndromes / prevention & control. Lacrimal Apparatus / pathology. Orbital Neoplasms / drug therapy. Orbital Neoplasms / radiotherapy. Radiation-Protective Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Neuroendocrine / radiotherapy. Female. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / radiotherapy. Male. Middle Aged. Pilot Projects

  • Bern Open Repository and Information System. Free Full text from BORIS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology (Williston Park). 1998 Aug;12(8):1155-62; discussion 1162-9 [11236308.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):739-47 [11849797.001]
  • [Cites] Anticancer Drugs. 2002 Mar;13(3):181-209 [11984063.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):818-23 [12377334.001]
  • [Cites] Arch Ophthalmol. 1969 Jul;82(1):10-4 [4183019.001]
  • [Cites] Am J Ophthalmol. 1991 Jan 15;111(1):106-8 [1985472.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1035-9 [11072160.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] CLAO J. 1995 Oct;21(4):221-32 [8565190.001]
  • [Cites] Ann Oncol. 1998 May;9(5):505-9 [9653491.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2007 Sep;245(9):1347-55 [17318564.001]
  • [Cites] Strahlenther Onkol. 1999 Nov;175 Suppl 4:30-3 [10584138.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3339-45 [11013273.001]
  • [Cites] J Am Dent Assoc. 1991 Mar;122(3):63-9 [2019691.001]
  • (PMID = 18761746.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Protective Agents; M487QF2F4V / Amifostine
  • [Other-IDs] NLM/ PMC2542992
  •  go-up   go-down


6. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puéchal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J: Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum; 2004 Apr;50(4):1270-6
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: There is no effective treatment for patients with primary Sjögren's syndrome (SS).
  • Since tumor necrosis factor alpha (TNF alpha) could be a key element in the pathogenesis of primary SS, we conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of infliximab in primary SS.
  • Secondary end points were values on each VAS separately, the number of tender and swollen joints, the basal salivary flow rate, results of the Schirmer test for lacrimal gland function, the focus score on labial salivary gland biopsy, the level of C-reactive protein, and the erythrocyte sedimentation rate evaluated at weeks 0, 10, and 22, as well as quality of life evaluated by use of the generic Short Form 36 questionnaire administered at weeks 0, 10, and 22.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antirheumatic Agents / administration & dosage. Sjogren's Syndrome / drug therapy
  • [MeSH-minor] Aged. Double-Blind Method. Humans. Immunoglobulin G / blood. Infliximab. Middle Aged. Quality of Life. Treatment Failure

  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arthritis Rheum. 2004 Dec;50(12):4077; author reply 4077-8 [15593208.001]
  • (PMID = 15077311.001).
  • [ISSN] 0004-3591
  • [Journal-full-title] Arthritis and rheumatism
  • [ISO-abbreviation] Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Immunoglobulin G; B72HH48FLU / Infliximab
  •  go-up   go-down


7. Li Y, Zhang TM, An YZ, Shi JT, Fu JD, Qiu E: [Clinical study of lacrimal gland tumor involving anterior and middle cranial fossae]. Zhonghua Yi Xue Za Zhi; 2006 Jun 20;86(23):1597-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of lacrimal gland tumor involving anterior and middle cranial fossae].
  • OBJECTIVE: To investigate the clinical manifestations of lacrimal gland tumor involving the anterior and middle cranial fossae and the effect of transcranial-orbital approach in treatment of such tumor.
  • METHODS: A retrospective study was conducted on the clinical data of 23 cases lacrimal gland tumor involving the anterior and middle cranial fossae confirmed by radiological examination, including 11 cases of adenoid cystic carcinoma, 6 cases of pleomorphic adenocarcinoma (malignant mixed tumor), 2 cases of adenocarcinoma, 1 case of squamous cell carcinoma, 1 case of ductal carcinoma, 1 case of mucoepidermoid carcinoma, and 1 case of benign mixed tumor, 15 males and 8 females, aged 42.5 (2 - 76), with a case history of 43 months (2 months to 27 years), with the chief complaints of progressive proptosis, disgenesia of the eye ball, and orbit pain, all undergoing transcranial-orbital operation from August 1998 to February. 2006.
  • Recurrence of tumor occurred in 4 cases, and 1 case died from distant metastasis of adenocarcinoma.
  • CONCLUSIONS: Malignant lacrimal gland tumors, mainly adenoid cystic carcinomas, incline to involve the anterior and middle cranial fossae.
  • Adequate orbital apex decompression and exposure of the tumor can result from suitable transcranial-orbital approach.
  • However, complete surgical excision is difficult, and the tumor has a tendency to recur post-operatively.
  • Suitable treatment strategy should by combination of operation with irradiation or chemotherapy.
  • [MeSH-major] Eye Neoplasms / pathology. Lacrimal Apparatus / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cranial Fossa, Anterior. Cranial Fossa, Middle. Craniotomy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16854296.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Tse DT, Finkelstein SD, Benedetto P, Dubovy S, Schiffman J, Feuer WJ: Microdissection genotyping analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Am J Ophthalmol; 2006 Jan;141(1):54-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdissection genotyping analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.
  • PURPOSE: To investigate the feasibility of integrating molecular analysis into standard histopathology for lacrimal gland adenoid cystic carcinoma (ACC), and to gain insights into the molecular pathogenesis of this tumor and its response to intraarterial cytoreductive chemotherapy (IACC) that is of clinical use.
  • METHODS: setting: Institutional. patient population: Nine consecutive patients with lacrimal gland ACC were treated with IACC, followed by orbital exenteration and chemoradiotherapy.
  • This case series was compared with a series of seven patients treated by conventional local therapies. intervention procedure: Gene analysis was performed on microdissected tissue samples.
  • Mutational allelotyping targeting nine genomic loci was performed with 15 polymorphic microsatellite markers situated in proximity to known tumor suppressor genes serving as markers for the presence of gene deletion. main outcome measure: A fractional mutation index was used to compare the acquired mutational load between different tumors having nonidentical patterns of microsatellite informativeness.
  • CONCLUSIONS: Microdissection genotyping holds promise as a clinical tool in integrating molecular analysis into standard histopathology to advance the understanding of lacrimal gland ACC tumorigenesis.
  • A unique time course for temporal mutation acquisition in ACC is proposed, consisting of 1p36 loss first.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Adenoid Cystic / genetics. Chromosomes, Human, Pair 1 / genetics. Eye Neoplasms / genetics. Lacrimal Apparatus Diseases / genetics. Loss of Heterozygosity. Microsatellite Repeats / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Genotype. Humans. Infusions, Intra-Arterial. Male. Microdissection. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / genetics. Orbit / surgery. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386976.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / P30 EY 014801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins
  •  go-up   go-down


9. Peng X, Li G, Wang J, Lu C, Shi Q: Papillary cystadenocarcinoma of the lacrimal gland. Ann Ophthalmol (Skokie); 2010;42 Spec No:15-9
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary cystadenocarcinoma of the lacrimal gland.
  • A 35-year-old man complained of progressive exophthalmos on the left eye for six months.
  • MRI revealed approximately 18 mm x 17 mm cyst neoplasm across the inner and outer muscle cone in the left orbital cavity.
  • The cyst wall of the tumor had the infiltration of the cancer cells and contained the residual lacrimal gland tissue.
  • The patient refused further cranio-orbital resection or preoperative/postoperative radiotherapy or chemotherapy.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology

  • Genetic Alliance. consumer health - Papillary cystadenocarcinoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21138145.001).
  • [ISSN] 1530-4086
  • [Journal-full-title] Annals of ophthalmology (Skokie, Ill.)
  • [ISO-abbreviation] Ann Ophthalmol (Skokie)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Lin SC, Kau HC, Yang CF, Yang MH, Tsai CC, Kao SC, Hsu WM: Adenoid cystic carcinoma arising in the inferior orbit without evidence of lacrimal gland involvement. Ophthal Plast Reconstr Surg; 2008 Jan-Feb;24(1):74-6
Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma arising in the inferior orbit without evidence of lacrimal gland involvement.
  • A 60-year-old woman sought treatment for right orbital fullness and intermittent headache.
  • Orbital exenteration followed by concurrent radiotherapy and chemotherapy was performed.
  • The lacrimal gland was uninvolved by tumor microscopically.
  • Although rare, adenoid cystic carcinoma must be considered in the differential diagnosis of an orbital tumor, because the unusual location of an orbital adenoid cystic carcinoma may make its early detection difficult.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Orbit / pathology. Orbit / radiography. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209657.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Tse DT, Benedetto P, Morcos JJ, Johnson TE, Weed D, Dubovy S: An atypical presentation of adenoid cystic carcinoma of the lacrimal gland. Am J Ophthalmol; 2006 Jan;141(1):187-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical presentation of adenoid cystic carcinoma of the lacrimal gland.
  • PURPOSE: To report a case of lacrimal gland adenoid cystic carcinoma (ACC) with an atypical initial presentation and to postulate an anatomical explanation for this unusual biologic behavior.
  • METHODS: An orbital magnetic resonance imaging study of a 58-year-old man who complained of progressive diplopia and orbital discomfort disclosed a soft tissue mass in the left cavernous sinus and orbital apex.
  • The left lacrimal gland and the contiguous bone appeared normal.
  • He underwent two cycles of intraarterial cytoreductive chemotherapy followed by a left medial maxillectomy with sphenoethmoidectomy, orbital exenteration, and chemoradiation.
  • ACC tumor cells were identified in nerve fiber bundles surrounding and within the lacrimal gland.
  • CONCLUSIONS: In patients presenting with an infiltrative mass in the cavernous sinus or orbital apex, metastatic disease from an occult lacrimal gland primary should be considered, even with a normal-appearing lacrimal gland.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Orbital Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16386996.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / P30 EY 014801
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Hadjistilianou T, de Francesco S, Signori C, Menicacci F, Galluzzi P, Toti P: Pleomorphic adenoma of the lacrimal gland in an 18-year-old girl irradiated for bilateral retinoblastoma. Orbit; 2006 Mar;25(1):51-3
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma of the lacrimal gland in an 18-year-old girl irradiated for bilateral retinoblastoma.
  • PURPOSE: To report a case of pleomorphic adenoma of the lacrimal gland following irradiation for bilateral retinoblastoma.
  • A 4-month-old girl, with bilateral retinoblastoma, underwent enucleation of the right eye, systemic chemotherapy and bilateral external beam irradiation with a lateral field.
  • The right anophthalmic socket (because of infiltration of the optic nerve) and the left eye (for relapse) were irradiated;.
  • 17 years later, she developed a mass in the superotemporal quadrant of the left orbit.
  • In this case, it developed as a second primary tumor after irradiation for retinoblastoma.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Lacrimal Apparatus / pathology. Neoplasms, Radiation-Induced / pathology. Retinal Neoplasms / radiotherapy. Retinoblastoma / radiotherapy. Retinoblastoma / secondary
  • [MeSH-minor] Adolescent. Biopsy, Needle. Eye Enucleation. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Radiotherapy, Adjuvant. Risk Assessment. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527777.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


13. Raja M, Akhtar S, El Weshi A, Maghfoor I: Extrapulmonary small cell carcinoma (EPSCC): Retrospective review from a single institution. J Clin Oncol; 2004 Jul 15;22(14_suppl):6108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We therefore decided to review our institution's experience with EPSCC with special emphasis on treatment considerations.
  • METHODS: We used tumor registry records to identify all patients diagnosed with EPSCC at our institution.
  • Data were collected on demographics, site/s of disease, management, and outcome.
  • Sites of origin were esophagus 7, cervix 6, parotid gland, lacrimal gland, urinary bladder, pancreas, and anal canal 2 each, and prostate 1.
  • Initial therapy consisted of chemotherapy in 11, surgery in 6, radiation therapy in 6, and no treatment in 1.
  • Fourteen patients received chemotherapy (including 11 as initial treatment).
  • Chemotherapy regimens included etoposide/platinum in 8, etoposide combinations in 2, cytoxan/doxorubicin/vincristine/etoposide in 4.
  • At the completion of all therapy complete response was observed in 9, partial response in 3, stable disease in 1, progressive disease in 4 and not evaluable in 7.
  • Four of these were treated with combination of chemotherapy and local treatment.
  • Patients presenting with localized disease should be treated aggressively with combined modality therapy including chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Falchook GS, Wheler JJ, Tannir NM, Naing A, Jackson E, Hong D, Lawhorn KN, Ng C, Amin H, Kurzrock R: Hypoxia-inducible factor-1α (HIF-1α) modulation in combination with anti-angiogenic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):3555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-inducible factor-1α (HIF-1α) modulation in combination with anti-angiogenic therapy.
  • : 3555 Background: HIF-1α mediates adaptive responses to hypoxic conditions induced by anti-angiogenic therapy.
  • METHODS: Patients with advanced malignancy refractory to standard therapy were eligible.
  • Pharmacodynamic assessment included plasma VEGF, VEGFR2, 20S proteasome inhibition, DCE-MRI, and tumor expression of HIF-1α, VEGF, VEGFR2, and polymorphisms of VEGF and VEGFR2.
  • Minor responses or stable disease lasting ≥4 months was achieved in 8 patients, including RCC (1), breast (1), leiomyosarcoma (1), nasopharyngeal (2), hepatocellular (1), neuroendocrine (1), lacrimal gland adenocystic carcinoma (1).
  • The most common drug-related toxicities observed included hypertension (36%), fatigue (34%), thrombocytopenia (29%), and myalgia (19%).
  • 22 patients (31%) experienced no drug-related toxicities greater than grade 1.
  • 56 patients (79%) experienced no drug-related toxicities greater than grade 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961363.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Shet T, Ramadwar M, Sharma S, Laskar S, Arora B, Kurkure P: An eyelid sialoblastoma-like tumor with a sarcomatoid myoepithelial component. Pediatr Dev Pathol; 2007 Jul-Aug;10(4):309-14
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An eyelid sialoblastoma-like tumor with a sarcomatoid myoepithelial component.
  • Nonround cell tumors are rare in children and often difficult to diagnose.
  • Histologically, the tumor had nests of basaloid and relatively round cells with immature acinar or ductular structures similar to those seen in a conventional sialoblastoma, but these nests were embedded in a malignant spindle cell stroma.
  • This stroma on immunohistochemistry was marked with S-100 and cytokeratin, which, in combination with the pertinent ultrastructural evidence, indicated a myoepithelial differentiation.
  • Overall histologic features suggested a tumor similar to a sialoblastoma with sarcomatoid transformation of the myoepithelial component, hitherto not described in literature.
  • This tumor probably arose from the palpebral lobe of the lacrimal gland.
  • Postsurgery, the patient received chemotherapy (6 cycles of ifosfamide, vincristine, and doxorubicin hydrochloride [Adriamycin]) and local radiotherapy in view of residual disease.
  • Three months after completion of the treatment (1 year after surgery), the patient is well, without any local disease.
  • Awareness of this unusual histology of sialoblastoma will help in avoiding misdiagnosis and also refine treatment-related issues on this rare tumor.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Combined Modality Therapy. Desmosomes / ultrastructure. Disease-Free Survival. Humans. Immunohistochemistry. Infant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638426.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Bernardini FP, Devoto MH, Croxatto JO: Epithelial tumors of the lacrimal gland: an update. Curr Opin Ophthalmol; 2008 Sep;19(5):409-13
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial tumors of the lacrimal gland: an update.
  • PURPOSE OF REVIEW: The goal of this article is to offer an update on the treatment and prognosis of the most common epithelial tumors of the lacrimal gland, report on new pathological entities and offer a review of the classification of lacrimal gland tumors.
  • RECENT FINDINGS: Improvements have been made in the understanding of lacrimal gland lesions with the knowledge that lacrimal gland tumors compare to the more common counterparts of the major salivary glands.
  • Therefore, the WHO's classification of salivary gland tumors has been adapted to the lacrimal gland pathology.
  • Until recently, primary adenocarcinomas of the lacrimal gland were not further subclassified, but they can now be divided into low-grade and high-grade malignancies.
  • The adjunctive use of intra-arterial cytoreductive chemotherapy for the management of adenoid cystic carcinoma is one of the most important advancements on the management of these aggressive tumors.
  • Another important step forward has been taken on carcinoma ex pleomorphic adenoma of the lacrimal gland, which is subclassified into noninvasive carcinoma, with an excellent prognosis after complete excision and invasive carcinoma for which the prognosis is still guarded despite adjunctive radiotherapy.
  • SUMMARY: This article offers an update on diagnosis, classification and treatment of common and rare epithelial lacrimal gland tumors.
  • [MeSH-major] Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology. Neoplasms, Glandular and Epithelial / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772674.001).
  • [ISSN] 1531-7021
  • [Journal-full-title] Current opinion in ophthalmology
  • [ISO-abbreviation] Curr Opin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


17. Hassan AS, Elner VM: Orbital peripheral T-cell lymphoma in a child. Ophthal Plast Reconstr Surg; 2005 Sep;21(5):385-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy revealed peripheral T-cell lymphoma and associated necrosis involving the lacrimal gland and surrounding orbital tissue.
  • Immunohistochemical and T-cell receptor gene rearrangement studies confirmed the diagnosis.
  • The patient responded to local radiation and systemic chemotherapy.
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Biomarkers, Tumor / metabolism. Biopsy. Child. Combined Modality Therapy. Gene Rearrangement, T-Lymphocyte / genetics. Humans. Male. Receptors, Antigen, T-Cell, gamma-delta / genetics. Tomography, X-Ray Computed. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234707.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Receptors, Antigen, T-Cell, gamma-delta; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


18. Charlotte F, Doghmi K, Cassoux N, Ye H, Du MQ, Kujas M, Lesot A, Mansour G, Lehoang P, Vignot N, Capron F, Leblond V: Ocular adnexal marginal zone B cell lymphoma: a clinical and pathologic study of 23 cases. Virchows Arch; 2006 Apr;448(4):506-16
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better characterize ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue (MZL-MALT), we analyzed the clinical and pathologic features of 23 patients (11 men, 12 women, median age 66 years).
  • The tumor was confined to one ocular structure in 18 cases (conjunctiva, n=8; orbit, n=8; or lacrimal gland, n=2).
  • Concurrent extraorbital disease was detected by the staging procedure in five patients, and preferentially involved other MALT sites.
  • Histogenetic B cell marker studies, available in 13 cases, showed an early post-germinal center (GC) phenotype (BCL-6(-)/IRF4(+)/CD138(-)) (n=5) or a late post-GC phenotype (BCL-6(-)/IRF4(+)/CD138(+)) (n=8), which could be helpful for discrimination from other types of small-B cell lymphoma.
  • Regardless of the disease stage at diagnosis, combined chemotherapy and radiotherapy seemed to be more effective than chemotherapy alone in ocular adnexal MZL-MALT, as persistent complete remission was achieved in nine patients receiving combination therapy, while six of 14 patients treated with chemotherapy alone relapsed.
  • [MeSH-major] Eye Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Nucleus / chemistry. Cell Nucleus / pathology. Combined Modality Therapy. Cytoplasm / chemistry. Cytoplasm / pathology. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. Germinal Center / chemistry. Germinal Center / pathology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Remission Induction. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2002 Aug;118(2):216-24 [12162681.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1286-94 [11984515.001]
  • [Cites] Am J Hematol. 2003 Jun;73(2):87-96 [12749009.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):641-9 [11454995.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):807-12 [10702396.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Leukemia. 2000 Nov;14 (11):1967-74 [11069033.001]
  • [Cites] Mod Pathol. 2003 May;16(5):445-52 [12748251.001]
  • [Cites] Ophthalmology. 1986 Dec;93(12):1547-57 [3543790.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Am J Surg Pathol. 1989 Jun;13(6):459-71 [2658631.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Br J Ophthalmol. 2005 Mar;89(3):352-9 [15722318.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):959-73 [2394438.001]
  • [Cites] Histopathology. 1990 Jun;16(6):617-9 [2376404.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Dec;8(4):263-6 [11127917.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1182-7 [11493468.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):214-26 [10623712.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1012-8 [12676782.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1147-54 [11021819.001]
  • [Cites] Ophthalmology. 1985 Oct;92(10):1311-24 [3906488.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1433-9 [10751367.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1430-41 [9709754.001]
  • [Cites] Ophthalmology. 2005 Jan;112(1):114-9 [15629830.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):13-8 [15309523.001]
  • [Cites] Leuk Lymphoma. 1999 Feb;32(5-6):533-43 [10048426.001]
  • [Cites] Mol Cell. 2000 Oct;6(4):961-7 [11090634.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1183-8 [10751343.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2220-8 [9746758.001]
  • [Cites] Clin Exp Ophthalmol. 2001 Dec;29(6):387-93 [11778809.001]
  • [Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]
  • [Cites] Blood. 1995 Jul 1;86(1):45-53 [7795255.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):1994-2006 [9098307.001]
  • [Cites] Jpn J Cancer Res. 2000 Mar;91(3):301-9 [10760689.001]
  • [Cites] Pathol Int. 2004 Jan;54(1):16-25 [14674990.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19012-9 [11262391.001]
  • [Cites] Br J Ophthalmol. 2001 Jan;85(1):63-9 [11133714.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):742-51 [11395551.001]
  • [Cites] Lancet. 1986 Jun 14;1(8494):1346-9 [2872470.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):779-81 [9739446.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):269-73 [12688344.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Br J Ophthalmol. 1999 Jun;83(6):742-7 [10340987.001]
  • [Cites] Histopathology. 1993 Nov;23(5):417-24 [8314214.001]
  • [Cites] Cell. 2001 Jan 12;104(1):33-42 [11163238.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):454-7 [10945490.001]
  • (PMID = 16323006.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


19. Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM: Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys; 2003 Sep 1;57(1):49-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation.
  • PURPOSE: To review the University of California-San Francisco (UCSF) experience of using intensity-modulated radiation therapy (IMRT) to treat head-and-neck cancer focusing on the importance of target volume delineation and adequate target volume coverage.
  • Sites included were nasopharynx 86, oropharynx 22, paranasal sinus 22, thyroid 6, oral tongue 3, nasal cavity 2, salivary 2, larynx 2, hypopharynx 1, lacrimal gland 1, skin 1, temporal bone 1, and trachea 1.
  • One hundred seven patients were treated definitively with IMRT +/- concurrent platinum chemotherapy (92/107), whereas 43 patients underwent gross surgical resection followed by postoperative IMRT +/- concurrent platinum chemotherapy (15/43).
  • The gross target volume (GTV) was defined as tumor detected on physical examination or imaging studies.
  • In postoperative cases, the GTV was defined as the preoperative gross tumor volume.
  • The clinical target volume (CTV) included all potential areas at risk for microscopic tumor involvement by either direct extension or nodal spread including a margin for patient motion and setup errors.
  • The average prescription doses to the GTV were 70 Gy and 66 Gy for the primary and the postoperative cases, respectively.
  • The site of recurrence was determined by the diagnostic neuroradiologist to be either within the GTV or the CTV volume by comparison of the treatment planning computed tomography with posttreatment imaging studies.
  • RESULTS: For the primary definitive cases with a median follow-up of 25 months (range 6 to 78 months), 4 patients failed in the GTV.
  • For the primary group, the average maximum, mean, and minimum doses delivered were 80 Gy, 74 Gy, 56 Gy to the GTV, and 80 Gy, 69 Gy, 33 Gy to the CTV.
  • For the postoperative group, the average maximum, mean, and minimum doses delivered were 79 Gy, 71 Gy, 37 Gy to the GTV and 79 Gy, 66 Gy, 21 Gy to the CTV.
  • CONCLUSION: Accurate target volume delineation in IMRT treatment for head-and-neck cancer is essential.
  • Higher treatment failure rates were noted in the postoperative setting in which lower doses were prescribed.
  • [MeSH-major] Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / radiotherapy. Imaging, Three-Dimensional / methods. Neoplasm Recurrence, Local / epidemiology. Radiotherapy Planning, Computer-Assisted / methods
  • [MeSH-minor] Academic Medical Centers. Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / methods. Radiotherapy, Conformal / methods. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1639; author reply 1639-40 [15050350.001]
  • (PMID = 12909215.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Robinson JW, Brownstein S, Jordan DR, Hodge WG: Conjunctival mucoepidermoid carcinoma in a patient with ocular cicatricial pemphigoid and a review of the literature. Surv Ophthalmol; 2006 Sep-Oct;51(5):513-9
Hazardous Substances Data Bank. Ofloxacin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The woman was undergoing mitomycin C injections for ocular cicatricial pemphigoid, diagnosed in the same eye 2 years prior to identification of the neoplasm.
  • The tumor invaded the cornea, sclera, lacrimal gland, regional small nerves, and lymphatics, but did not show intraocular involvement.
  • [MeSH-minor] Basement Membrane / pathology. Biopsy. Drug Therapy, Combination. Female. Fluorometholone / therapeutic use. Humans. Middle Aged. Mitomycin / therapeutic use. Neoplasm Invasiveness. Ofloxacin / therapeutic use


21. Matmati K, Matmati N, Hannun YA, Rumboldt Z, Patel S, Lazarchick J, Stuart R, Giglio P: Dural MALT lymphoma with disseminated disease. Hematol Rep; 2010 Jan 26;2(1):e10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central nervous system (CNS) lymphoma involving the dura mater is very rare and histologically is usually a subtype of non-Hodgkin's lymphoma (NHL) termed mucosa-associated lymphoid tissue (MALT) lymphoma.
  • We present a case of a 46-year old woman with dural MALT lymphoma that was found to also involve a lacrimal gland, inguinal lymph nodes, and bone marrow.
  • She had recurrence in the subcutaneous tissue of the back at 12 months but has remained free of intracranial disease for 31 months.
  • Only 4 had extra-CNS involvement at presentation, and only 3 had local recurrence of the dural tumor.
  • Because of the indolent behavior of this tumor, the intracranial portion can be treated conservatively after resection with or without chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22184513.001).
  • [ISSN] 2038-8330
  • [Journal-full-title] Hematology reports
  • [ISO-abbreviation] Hematol Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3222263
  • [Keywords] NOTNLM ; Chemotherapy / Dural lymphoma / MALT lymphoma / Meningioma. / Radiation
  •  go-up   go-down


22. Stacy RC, Jakobiec FA, Schoenfield L, Singh AD: Unifocal and multifocal reactive lymphoid hyperplasia vs follicular lymphoma of the ocular adnexa. Am J Ophthalmol; 2010 Sep;150(3):412-426.e1
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: RLH preferentially involved the conjunctiva, whereas follicular lymphoma had a propensity to involve the lacrimal gland.
  • None of the patients with RLH developed lymphoma during their clinical courses (up to 18 years).
  • However, 3 patients with orbital, but not conjunctival, RLH developed immunohistochemically proven multifocal nonophthalmic supradiaphragmatic adnexal RLH (sites included lung, parotid, axillary nodes, and uvea).
  • CONCLUSIONS: A correct diagnosis of RLH vs follicular lymphoma can be reliably established employing immunohistochemical methods.
  • Conjunctival RLH can usually be managed surgically without radiotherapy, but "multifocal RLH" required systemic treatment in 2 of 3 patients.
  • Follicular lymphoma requires systemic chemotherapy if discovered beyond stage 1E.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Conjunctival Neoplasms / diagnosis. Lymphoma, Follicular / diagnosis. Neoplasm Proteins / metabolism. Orbital Neoplasms / diagnosis. Pseudolymphoma / diagnosis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • [ErratumIn] Am J Ophthalmol. 2010 Dec;159(6):943
  • (PMID = 20599186.001).
  • [ISSN] 1879-1891
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


23. Tang DR, Shi XF, Sun FY, Zhao H, Jin YJ: [Clinical features and therapy of benign lymphoepithelial lesion]. Zhonghua Yan Ke Za Zhi; 2009 May;45(5):441-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and therapy of benign lymphoepithelial lesion].
  • OBJECTIVE: To report the clinical features of benign lymphoepithelial lesion and to further characterize recommendations for its therapy strategy.
  • Retrospective analyze the clinical characteristics, imaging features, pathological manifestation and the treatment effect from the clinical materials of 9 cases of patients with benign lymphoepithelial lesion presenting to Tianjin Eye Hospital from Jan 2006 to Dec 2007.
  • RESULTS: The 9 cases, in which 7 cases were female, 7 cases had lesions on both eyes, demonstrated unpainful swelling of the lacrimal glands and in different degree of salivary glands or had history of tumor resection of salivary glands.
  • Orbital CT scanning showed increased homogeneous density with clear boundary in the lacrimal gland area.
  • Color doppler ultrasonography displayed elliptical space occupying with clear boundary and homogeneous internal echos of the lacrimal gland area.
  • Six patients received treatment with large dose of glucocorticoid for 1 - 2 courses, and the symptoms and signs were significantly alleviated.
  • Three patients were operated to excise the lacrimal gland masses due to imperfect treatment effect of medication or in order to make definite diagnosis.
  • The postoperative pathological results supported the diagnosis of benign lymphoepithelial lesion.
  • CONCLUSIONS: A clinical condition with swelling of either or both lacrimal gland and of any salivary gland, and accompanied with systemic relative diseases should be considered benign lymphoepithelial lesion.
  • Imaging examinations are helpful to definite diagnosis.
  • Most patients are sensitive to the glucocorticoid treatment.
  • The dose of glucocorticoid should be large at the beginning of treatment.
  • Surgical excision can be applied to the cases insensitive to medications or difficult to be diagnosed.
  • The definite diagnosis should be made through pathological examinations.
  • [MeSH-major] Mikulicz' Disease / diagnosis. Mikulicz' Disease / drug therapy
  • [MeSH-minor] Adult. Female. Glucocorticoids / therapeutic use. Humans. Lacrimal Apparatus. Male. Middle Aged. Retrospective Studies. Salivary Glands

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19576068.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


24. Krásný J, Sach J, Brunnerová R, Konvicka J, Jankovská M, Srp A, Kozák J: [Orbital tumors in adults--a 10-year study]. Cesk Slov Oftalmol; 2008 Nov;64(6):219-27

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orbital tumors in adults--a 10-year study].
  • The authors refer about diagnostic procedures, treatment and follow-up of 87 adult patients with orbital tumors during the period 1998 - 2007 in the Department of Ophthalmology, Faculty Hospital Královské Vinohrady, Charles University, Prague, Czech Republic, E.U.
  • In 49 patients, the tumors were of benign origin (age 18-80 years, median, 48 years), and 38 patients suffered from malign tumors (age 38-89 years, median, 61 years).
  • Among basic examinations methods ranked the magnetic resonance imaging and the histological verification of the tumor.
  • Sixty-four tumors were treated by means of 70 surgical procedures.
  • The anterior diagnostic or therapeutic orbitotomy was used in 72.5% of the cases, lateral osteoplastic orbitotomy (Kronlein) in 14.5%, and exenteration of the orbit in 13% of the cases.
  • Altogether 23 patients were treated without surgery by means of corticosteroids, or are followed-up due to a benign tumor only.
  • All patients were treated by means of prednisolon for at least three months; due to the relapse of the immunopathologic process, in 16 % of the cases the therapy was supplemented with azathioprime.
  • The surgical procedure was the choice of treatment in 66% of inflammatory processes in the lacrimal gland region.
  • In four cases the sarcoidosis was established.The second tumor in the final ranking was lymphoma in 19.5%; the MALT-lymphoma was diagnosed in 59% of these cases.
  • The chemotherapy was chosen for the treatment in 2/3 of the cases, and in all cases the remission was reached.The actinotherapy was chosen especially in other types of lymphoma; the follicular form and "molding" lymphoma were the causes of the death in two patients.
  • Among malignant tumors, the most serious clinical courses were histological different primary carcinomas of the orbitopalpebral region in 14% of the cases, and secondary melanoma spreading from the conjunctiva in 5.5%.
  • Both these tumors, counting the same number as lymphomas, were the only indications to the exenteration of the orbit, and causes of the death in four patients.
  • CONCLUSION: Among orbital tumors in adults, the most common were inflammatory pseudotumor and lymphoma.
  • The decisive procedure was always the histological verification, which directed the following therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110961.001).
  • [ISSN] 1211-9059
  • [Journal-full-title] Ceská a slovenská oftalmologie : casopis Ceské oftalmologické spolecnosti a Slovenské oftalmologické spolecnosti
  • [ISO-abbreviation] Cesk Slov Oftalmol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


25. Fox RI, Stern M, Michelson P: Update in Sjögren syndrome. Curr Opin Rheumatol; 2000 Sep;12(5):391-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sjögren syndrome (SS), the second most common autoimmune rheumatic disease, refers to keratoconjunctivitis sicca and xerostomia resulting from immune lymphocytes that infiltrate the lacrimal and salivary glands.
  • However, differential diagnosis remains confusing due to the high prevalence of vague symptoms of dryness, fatigue, and myalgias in the general population.
  • The problems of diagnosis are further compounded by the finding of "positive" antinuclear antibodies in a high percent of the general population.
  • Unless minor salivary gland biopsies are read by experienced observers, nonspecific changes of sialadenitis are frequently confused with the focal lymphocytic infiltrates that are characteristic of SS.
  • Even in SS patients with marked sicca symptoms, minor salivary gland biopsy shows that almost 50% of glandular cells are still detected on biopsy.
  • Newly developed topical and oral therapies can ease the oral and ocular dryness.
  • Orally administered agonists of the muscarinic M3 receptor (pilocarpine and cevimeline) have recently been approved by the US Food and Drug Administration to increase salivary secretion.
  • In animal models, antagonists of tumor necrosis factor and inhibitors of de novo pyrimidine synthesis appear promising.
  • [MeSH-minor] Adult. Animals. Anti-Inflammatory Agents / therapeutic use. Autoantibodies. Cardiovascular Diseases / etiology. Central Nervous System Diseases / etiology. Dexamethasone / therapeutic use. Female. Fetal Distress / drug therapy. Fetal Distress / etiology. Humans. Muscarinic Agonists / therapeutic use. Pregnancy. Saliva / secretion. Skin Diseases / etiology. Xerophthalmia / etiology

  • Genetic Alliance. consumer health - Sjogren Syndrome.
  • MedlinePlus Health Information. consumer health - Sjogren's Syndrome.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10990175.001).
  • [ISSN] 1040-8711
  • [Journal-full-title] Current opinion in rheumatology
  • [ISO-abbreviation] Curr Opin Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Autoantibodies; 0 / Muscarinic Agonists; 7S5I7G3JQL / Dexamethasone
  • [Number-of-references] 108
  •  go-up   go-down


26. Hug EB, Adams J, Fitzek M, De Vries A, Munzenrider JE: Fractionated, three-dimensional, planning-assisted proton-radiation therapy for orbital rhabdomyosarcoma: a novel technique. Int J Radiat Oncol Biol Phys; 2000 Jul 1;47(4):979-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated, three-dimensional, planning-assisted proton-radiation therapy for orbital rhabdomyosarcoma: a novel technique.
  • However, conventional photon-radiation treatment, as part of multimodality therapy, results in varying degrees of long-term functional and cosmetic side effects.
  • This report introduces external beam proton radiation therapy (PRT) as a conformal, three-dimensional planned radiation technique for this disease, analyzes normal tissue dosimetry, and describes the technique's application in the first 2 patients.
  • MATERIAL AND METHODS: Between January 1995 and February 1996, 2 patients underwent PRT following biopsy and chemotherapy for orbital rhabdomyosarcoma.
  • Fifty and 55 Cobalt Gray Equivalent (CGE) were delivered to the gross tumor volume and 40 CGE to clinical target volumes in both patients.
  • Dose-volume histograms were obtained for target and nontarget regions, including lens, bony orbit, pituitary gland, optic chiasm, optic nerves, lacrimal gland, and ipsilateral frontal and temporal lobes.
  • Fifty percent of lacrimal gland volume received less than 36% of the prescribed dose and 50% of the volume of the optic chiasm, pituitary gland, and hypothalamus were restricted to less than 2%.
  • The steep dose gradient beyond the orbit minimizes irradiation of normal brain parenchyma, with almost complete sparing of the pituitary gland.
  • [MeSH-major] Orbital Neoplasms / radiotherapy. Protons / therapeutic use. Radiotherapy, Conformal / methods. Rhabdomyosarcoma / radiotherapy
  • [MeSH-minor] Child. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Orbit / radiography. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10863068.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down






Advertisement